MED: Endocrinology Flashcards

1
Q

What is acromegaly?

A

Disorder caused by excessive secretion of growth hormone (GH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the cause of acromegaly?

A

Pituitary adenoma in over 95% of cases

A minority of cases are caused by ectopic GHRH or GH production by tumours e.g. pancreatic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the clinical features of acromegaly?

A
  • coarse facial appearance
  • spade-like hands
  • increase in shoe size
  • large tongue, prognathism, interdental spaces
  • excessive sweating and oily skin: caused by sweat gland hypertrophy
  • features of pituitary tumour: hypopituitarism, headaches, bitemporal hemianopia
  • raised prolactin in 1/3 of cases → galactorrhoea
  • 6% of patients have MEN-1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the investigations for acromegaly?

A

First line: Serum IGF-1 levels

If raised:

Second line: OGTT

  • In normal patients GH is suppressed to <2mu/L with hyperglycaemia
  • In acromegaly there is no suppression of GH

A pituitary MRI may demonstrate a pituitary tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the management of acromegaly?

A

Trans-sphenoidal surgery:

  • First-line in majority of patients

Dopamine agonists:

  • E.g. bromocriptine
  • Now superseded by somatostatin analogues
  • Effective only in a minority of patients

Somatostatin analogues:

  • Directly inhibits release of GH
  • E.g. octreotide
  • May be used as an adjunct to surgery

Pegvisomant:

  • GH receptor antagonist
  • Once daily s/c administration
  • Very effective - decreases IGF-1 levels in 90% of patients to normal
  • Doesn’t reduce tumour volume therefore surgery still needed if mass effect

External irradiation is sometimes used for older patients or following failed surgical/medical treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the complications of acromegaly?

A
  • hypertension
  • diabetes (>10%)
  • cardiomyopathy
  • colorectal cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Addison’s disease?

A

// Primary adrenal insufficiency

Disorder characterized by inadequate production of cortisol and aldosterone by the adrenal cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the causes of Addison’s disease?

A
  • Autoimmune destruction of adrenal cortex - most common cause (70-90%)
  • Infections* - TB, fungal infections, HIV, and CMV
  • Genetic disorders - CAH, APS-1
  • Metastatic infiltration - lung, breast, or melanoma can metastasize to adrenals
  • Adrenal haemorrhage - trauma, anticoagulation, sepsis
  • Medications - prolonged use of glucocorticoids or drugs that inhibit steroidogenesis (e.g., ketoconazole) can suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal atrophy and insufficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does the adrenal insufficiency in Addison’s cause?

A

Cortisol deficiency:

  • Cortisol is crucial for maintaining glucose homeostasis, immune function, and stress response. - Reduced cortisol production results in hypoglycemia, increased susceptibility to infections, and an inadequate response to stressors.

Aldosterone deficiency:

  • Aldosterone is responsible for regulating sodium and potassium balance.
  • Insufficient aldosterone production leads to hyponatremia, hyperkalemia, and volume depletion, causing orthostatic hypotension and impaired renal function.

Adrenal androgens deficiency:

  • Although their role is less prominent, adrenal androgens are involved in secondary sexual characteristics and libido.
  • A deficiency may result in reduced body hair and decreased libido.

Increased ACHT: (loss of neg feedback)

  • Elevated ACTH levels result in melanocyte-stimulating hormone (MSH) production, causing the characteristic hyperpigmentation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the clinical features of Addison’s disease?

A
  • lethargy, weakness
  • anorexia, nausea & vomiting, weight loss, ‘salt-craving’
  • hyperpigmentation (especially palmar creases)
  • vitiligo
  • loss of pubic hair in women
  • hypotension,
  • hypoglycaemia
  • hyponatraemia and hyperkalaemia may be seen
  • crisis: collapse, shock, pyrexia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the investigations for Addison’s?

A

ACTH stimulation test (short Synacthen test):

  • Plasma cortisol is measured before and 30 minutes after giving Synacthen 250ug IM
  • Normal response = rise in blood cortisol levels
  • Addison’s = little or no increase in cortisol levels

If ACTH stimulation test not readily available (e.g. in primary care):

9 am serum cortisol:

  • > 500 nmol/l = Addison’s very unlikely
  • <100 nmol/l = definitely abnormal
  • 100-500 nmol/l = perform ACTH stimulation

Adrenal autoantibodies:

  • Presence of 21-hydroxylase autoantibodies supports autoimmune adrenalitis as underlying cause

Associated electrolyte abnormalities:

  • hyperkalaemia
  • hyponatraemia
  • hypoglycaemia
  • metabolic acidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the management of Addison’s?

A

Glucocorticoid and mineralocorticoid replacement therapy:

  • hydrocortisone
  • fludrocortisone

Patient education:

  • emphasise the importance of not missing glucocorticoid doses
  • consider MedicAlert bracelets and steroid cards
  • patients should be provided with hydrocortisone for injection with needles and syringes to treat an adrenal crisis
  • discuss how to adjust the glucocorticoid dose during an intercurrent illness (see below)

Management of intercurrent illness:

  • glucocorticoid dose should be doubled, with fludrocortisone dose staying the same
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is an adrenal crisis?

A

An acute life-threatening condition characterized by severe hypotension, hypoglycemia, and altered mental status.

Immediate treatment with IV hydrocortisone, fluids, and electrolyte correction is crucial.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is Cushing’s disease?

A

Disorder caused by the overproduction of cortisol hormone by the adrenal glands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the causes of Cushing’s disease?

A

Most commonly caused by a benign pituitary tumour that secretes ACTH, which stimulates the adrenal glands to produce cortisol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the clinical features of Cushing’s disease?

A
  • Central Obesity and Weight Gain - moon facies, buffalo hump
  • Abdominal striae, typically purple or violaceous in colour
  • Proximal myopathy affecting the hip and shoulder girdles, leading to difficulty in rising from a seated position or climbing stairs
  • Osteopenia and osteoporosis with an increased risk of fractures
  • Avascular necrosis of the femoral head
  • Hirsutism due to increased adrenal androgens
  • Acne vulgaris and seborrheic dermatitis
  • Thin skin with easy bruising and poor wound healing
  • Glucose intolerance or overt type 2 diabetes mellitus
  • Menstrual irregularities (oligomenorrhea or amenorrhea) in females
  • Decreased libido and erectile dysfunction in males
  • Depression, anxiety, irritability, emotional lability, and cognitive deficits such as impaired memory or concentration
  • Sleep disturbances including insomnia or hypersomnia
  • Hypertension
  • Increased risk of VTE
  • In children, growth retardation may occur due to cortisol-mediated suppression of GH secretion
  • Precocious puberty may be observed in some cases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the management of Cushing’s syndrome?

A

Treatment options include surgical removal of the pituitary tumour, radiation therapy, and medication to control cortisol levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the management of Graves’ disease?

A

ß-blockers:

  • For rapid control of symptoms
  • E.g. propranolol.

Radioactive iodine:

  • First-line definitive treatment
  • Patients often become hypothyroid, thus may require replacement therapy.

Antithyroid drugs:

  • Offer a 12-18 month course as first-line definitive treatment if it is likely to achieve remission, or if radioactive iodine and surgery are unsuitable.
  • Examples include carbimazole (first-line) and propylthiouracil.

Surgery:

  • Total thyroidectomy offered as first-line definitive treatment if concerns about compression or malignancy, or radioactive iodine and antithyroid drugs unsuitable.
  • Consider if antithyroid drugs have been tried but hyperthyroidism persisted or relapsed.
  • Patients become hypothyroid, thus require replacement therapy.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are important exceptions to using radioactive iodine first-line?

A
  • Pregnancy
  • Attempts to conceive within the next 4-6 months
  • Presence of active eye disease
  • Concerns about compression or malignancy.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is a thyroid storm?

A

Thyroid storm is a rare but life-threatening complication of thyrotoxicosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the clinical features of a thyroid storm?

A
  • fever > 38.5ºC
  • tachycardia
  • confusion and agitation
  • nausea and vomiting
  • hypertension
  • heart failure
  • abnormal liver function test - jaundice may be seen clinically
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the management of a thyroid storm?

A

treated with beta-blockade, anti-thyroid drugs, and steroids

  • symptomatic treatment e.g. paracetamol
  • treatment of underlying precipitating event
  • beta-blockers: typically IV propranolol
  • anti-thyroid drugs: e.g. methimazole or propylthiouracil
  • Lugol’s iodine
  • dexamethasone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are some causes of hypoglycaemia?

A

Diabetes:

  • Excess insulin - most commonly from exogenous, injectable insulin - taken too much // used same amount whilst not eating enough or skipping a meal or snack.
  • Sulfonylureas (e.g. gliclazide) - esp when starting or increasing dose.
  • Viral illness, drunk alcohol, exercised more than usual or have just started or changed dosage of a new medication.

Non-diabetic causes:

  • Iatrogenic: indomethacin, pentamidine, quinine, sulfonamide, IGF-1 and lithium.
  • Alcohol consumption is the most common non-iatrogenic cause of hypoglycaemia

Rarer causes:

  • Hypopituitarism and Addison’s disease
  • Insulinoma - neuroendocrine tumour of the pancreas which causes unregulated secretion of insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the investigations for hypoglycaemia?

A
  • Serum insulin: elevated in insulinoma.
  • Serum C-peptide: elevated in insulinoma or sulfonylurea use.
  • Serum cortisol: reduced in adrenal insufficiency or hypopituitarism.
  • TSH, U&E, LFTs: abnormalities help identify secondary causes of hypoglycaemia such as hypothyroidism, chronic liver disease or kidney disease.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the investigations for an insulinoma?

A

48 to 72-hour fast with serial blood glucose, serum proinsulin, C-peptide and insulin levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is the management of hypoglycaemia?

A

If the patient is alert, a quick-acting carbohydrate may be given (GlucoGel or Dextrogel).

If the patient is unconscious or unable to swallow, SC or IM glucagon may be given.

Alternatively, IV 20% glucose solution may be given through a large vein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What are the causes of hypoparathyroidism?

A
  • Damage or inadvertent removal of the parathyroid glands during thyroid or neck surgery - most common
  • Autoimmune disorders
  • Congenital absence or dysfunction of the parathyroid glands
  • Certain genetic disorders like DiGeorge syndrome.
  • Rarely - magnesium deficiency or damage to the glands from radiation therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the clinical features of hypoparathyroidism?

A

Hypocalcaemia: > Neuromuscular irritability

  • Mild numbness or tingling of the extremities and around the mouth
  • Muscle cramps
  • Fatigue
  • Tetany
  • Carpopedal spasm
  • Laryngospasm
  • Seizures

Physical signs:

  • Chvostek’s sign (twitching of the facial muscles in response to tapping over the facial nerve)
  • Trousseau’s sign (carpopedal spasm induced by occluding the brachial artery with a blood pressure cuff).

Long-standing hypocalcaemia can also lead to extrapyramidal symptoms, cataracts, and calcification of the basal ganglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the investigations for hypoparathyroidism?

A

Bloods:

  • Low serum calcium
  • Low or inappropriately normal PTH levels in the presence of hyperphosphatemia
  • Elevated magnesium
  • Urinary calcium excretion may be low

ECG:

  • Prolonged QT interval due to hypocalcaemia.

Radiographs:

  • May reveal intracranial calcifications or changes in bone density.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the management of hypoparathyroidism?

A

Oral calcium supplements and active vitamin D analogues, such as calcitriol or alfacalcidol.

Patients should also be advised on dietary modifications, including a high-calcium, low-phosphorus diet.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What are the causes of primary hypothyroidism?

A
  • Hashimoto’s thyroiditis (autoimmune) - most common cause
  • Subacute thyroiditis (de Quervain’s)
  • Riedel thyroiditis
  • After thyroidectomy or radioiodine treatment
  • Drug therapy (e.g. lithium, amiodarone or anti-thyroid drugs such as carbimazole)
  • Dietary iodine deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What are causes of secondary hypothyroidism?

A

From pituitary failure

Other associated conditions:
Down’s syndrome
Turner’s syndrome
coeliac disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What is the management of hypothyroidism?

A

Levothyroxine:

  • BNF recommends that for patients with cardiac disease, severe hypothyroidism or patients over 50 > initial starting dose should be 25mcg od with dose slowly titrated.
  • Other patients should be started on a dose of 50-100mcg od
  • Following a change in thyroxine dose TFTs should be checked after 8-12 weeks
  • Women with established hypothyroidism who become pregnant should have their dose increased ‘by at least 25-50 micrograms levothyroxine’*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is Conn’s Syndrome?

A

Primary hyperaldosteronism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the causes of primary hyperaldosteroism?

A
  • bilateral idiopathic adrenal hyperplasia - most common
  • adrenal adenoma
  • unilateral hyperplasia
  • familial hyperaldosteronism
  • adrenal carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What are the clinical features of Conn’s?

A
  • hypertension
  • hypokalaemia - e.g. muscle weakness
  • metabolic alkalosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What are the investigations for Conn’s?

A

Plasma aldosterone/renin ratio:

  • first-line
  • high aldosterone levels alongside low renin levels

High-resolution CT abdomen:

  • used to differentiate between unilateral and bilateral sources of aldosterone excess

Adrenal vein sampling:

  • if CT is normal adrenal venous sampling (AVS) can be used to distinguish between unilateral adenoma and bilateral hyperplasia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the management of Conn’s?

A
  • adrenal adenoma: surgery (laparoscopic adrenalectomy)
  • bilateral adrenocortical hyperplasia: aldosterone antagonist e.g. spironolactone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What are the causes of primary hyperparathhyroidism?

A

85%: solitary parathyroid adenoma
10%: hyperplasia
4%: multiple adenoma
1%: carcinoma

40
Q

What inherited disorders are responsible for primary hyperparathyroidism?

A
  • Multiple endocrine neoplasia (MEN)
  • Hyperparathyroidism jaw tumour syndrome
  • Familial isolated primary hyperparathyroidism
41
Q

What are the clinical features of primary hyperparathyroidism?

A

S/S of hypercalcaemia:
‘stones, bones, abdominal groans and psychic overtones’

  • ‘Stones’ - increased risk of kidney stones
  • ‘Bones’ - Bone pain, Osteopenia and osteoporosis
  • ‘Abdominal groans’ - Abdominal pain, Constipation, N&V
  • ‘Psychic overtones’ - Fatigue, Depression, Memory impairment

Other features include polyuria, paresthesia and muscle cramps.

In severe cases, cardiac and metabolic disturbances, delirium or even coma may occur.

42
Q

What are the investigations for primary hyperparathyroidism?

A

Typically, both calcium and PTH should be raised, although a raised serum calcium and a normal PTH is also indicative of primary hyperparathyroidism. This is because the PTH levels are inappropriately high in the context of a raised calcium.

43
Q

What is the management of primary hyperparathyroidism?

A

Parathyroidectomy:
Surgery is indicated for those with one or more of:

  • Symptomatic disease - hypercalcaemia, Osteoporosis and/or fragility fractures, renal stones or nephrocalcinosis
  • Age <50 years
  • Serum adjusted calcium of 2.85 mmol/L or above
  • eGFR <60 mL/min/1.73 m²

When parathyroid surgery is not acceptable:

  • Calcitonin (reduces serum calcium concentrations)
  • Cinacalcet (reduces serum calcium concentrations)
  • Desunomab (impairs calcium resorption)
  • Bisphosphonates
44
Q

What are the clinical features of a prolactinoma?

A

excess prolactin in women

  • amenorrhoea
  • infertility
  • galactorrhoea
  • osteoporosis

excess prolactin in men
- impotence
- loss of libido
- galactorrhoea

other symptoms may be seen with macroadenomas

  • headache.
  • visual disturbances (classically, a bitemporal hemianopia (lateral visual fields) or upper temporal quadrantanopia)
  • symptoms and signs of hypopituitarism
45
Q

What are the phases of De Quervain’s thyroiditis?

A

phase 1 (lasts 3-6 weeks): hyperthyroidism, painful goitre, raised ESR

phase 2 (1-3 weeks): euthyroid

phase 3 (weeks - months): hypothyroidism

phase 4: thyroid structure and function goes back to normal

46
Q

What are the investigations for De Quervain’s thyroiditis?

A

thyroid scintigraphy: globally reduced uptake of iodine-131

47
Q

What is the management of De Quervain’s thyroiditis?

A
  • usually self-limiting - most patients do not require treatment
  • thyroid pain may respond to aspirin or other NSAIDs
  • in more severe cases steroids are used, particularly if hypothyroidism develops
48
Q

What are the investigations for toxic multinodular goitre?

A

In the absence of Graves’ disease stigmata and TSH receptor antibodies, and when biochemical hyperthyroidism is confirmed, thyroid scan and uptake are indicated:

Radioisotope scan:

  • In toxic MNG, the scan shows multiple hot and cold areas , consistent with areas of autonomy and suppression

Others:

  • ECG may be necessary for suspected dysrhythmia.
  • CT non-contrast Neck may be indicated for pre-operative evaluation.
49
Q

How is diabetes diagnosed?

A
  • Random plasma glucose level ≥11.1 mmol/L

OR

  • Fasting plasma glucose ≥7.0 mmol/L

OR

  • Plasma glucose level ≥11 mmol/L 2 hours after a 75 g oral glucose load (OGTT)

OR

  • HbA1c ≥48 mmol/mol (≥6.5%)

Symptomatic patient = single positive result Asymptomatic patient = repeat measurements of the same test on different days is required to confirm the diagnosis.

50
Q

What is Impaired fasting glucose and impaired glucose tolerance?

A

Impaired fasting glucose (IFG) = fasting glucose greater than or equal to 6.1 but less than 7.0 mmol/l

Impaired glucose tolerance (IGT) = fasting plasma glucose less than 7.0 mmol/l and OGTT 2-hour value greater than or equal to 7.8 mmol/l but less than 11.1 mmol/l

51
Q

What dietary advise should be offered to patients with diabetes?

A
  • encourage high fibre, low glycaemic index sources of carbohydrates
  • include low-fat dairy products and oily fish
  • control the intake of foods containing saturated fats and trans fatty acids
  • limited substitution of sucrose-containing foods for other carbohydrates is allowable, but care should be taken to avoid excess energy intake
  • discourage the use of foods marketed specifically at people with diabetes
  • initial target weight loss in an overweight person is 5-10%
52
Q

Describe HbA1c targets for people with diabetes

A

HbA1c should be checked every 3-6 months until stable, then 6 monthly

53
Q

Describe first line management in Type 2 Diabetes

A

Metformin:

  • Titrated up slowly to minimise the possibility of gastrointestinal upset
  • If standard-release metformin not tolerated then modified-release metformin should be trialled

SGLT-2 inhibitors:
Should also be given in addition to metformin if any of the following apply:

  • high risk of developing cardiovascular disease (CVD, e.g. QRISK ≥ 10%)
  • established CVD
  • chronic heart failure
  • patient develops CVD (e.g. is diagnosed with ischaemic heart disease), a QRISK ≥ 10% or chronic heart failure

metformin should be established and titrated up before introducing the SGLT-2 inhibitor

If metformin is contraindicated:
if the patient has a risk of CVD, established CVD or chronic heart failure:

  • SGLT-2 monotherapy

if the patient doesn’t have a risk of CVD, established CVD or chronic heart failure:

  • DPP‑4 inhibitor or pioglitazone or a sulfonylurea
  • SGLT-2 may be used if certain NICE criteria are met
54
Q

Describe further drug therapy for T2DM if HbA1c targets are not met

A

If the HbA1c has risen to 58 mmol/mol (7.5%) then further treatment is indicated.

Second-line therapy:
Dual therapy - add one of the following:

  • metformin + DPP-4 inhibitor
  • metformin + pioglitazone
  • metformin + sulfonylurea
  • metformin + SGLT-2 inhibitor (if NICE criteria met)

Third-line therapy:
If a patient does not achieve control on dual therapy then the following options are possible:

  • metformin + DPP-4 inhibitor + sulfonylurea
  • metformin + pioglitazone + sulfonylurea
  • metformin + (pioglitazone or sulfonylurea or DPP-4 inhibitor) + SGLT-2 if certain NICE criteria are met
  • insulin-based treatment

Further therapy:
If triple therapy is not effective or tolerated consider switching one of the drugs for a GLP-1 mimetic:

  • BMI ≥35 and specific psychological or other medical problems associated with obesity or
  • BMI < 35 and for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities

GLP-1 mimetics should only be added to insulin under specialist care

Starting insulin:

  • metformin should be continued.
  • In terms of other drugs NICE advice: ‘Review the continued need for other blood glucose-lowering therapies’
  • NICE recommend starting with human NPH insulin (isophane, intermediate-acting) taken at bed-time or twice daily according to need
55
Q

Describe the microvascular complications of diabetes

A

Diabetic Retinopathy:

  • damage to retinal vasculature, leading to microaneurysms, haemorrhages, and neovascularization.

Diabetic Nephropathy:

  • common cause of CKD and end-stage renal disease. - characterized by albuminuria, declining GFR, and eventually, renal failure.
  • Management strategies include blood glucose and blood pressure control, use of ACEIs or ARBs , and appropriate dietary modifications.

Diabetic Neuropathy:

  • range of nerve disorders, including peripheral neuropathy, autonomic neuropathy, and focal neuropathies.
  • Peripheral neuropathy, the most common form, presents with pain, numbness, and tingling in the extremities, increasing the risk of foot ulcers and amputations.
  • Autonomic neuropathy affects the autonomic nervous system, leading to gastrointestinal, cardiovascular, and genitourinary dysfunction.
  • Focal neuropathies involve damage to specific nerves, resulting in localized weakness or pain.
56
Q

Describe the macrovascular complications of diabetes

A

Coronary Artery Disease:

  • T2DM significantly increases the risk of CAD, myocardial infarction, and heart failure

Cerebrovascular Disease:

  • Patients with T2DM have an increased risk of stroke and TIAs due to atherosclerosis and thromboembolic events

Peripheral Artery Disease:

  • T2DM patients are at a higher risk of developing PAD, which can lead to intermittent claudication, critical limb ischemia, and amputations
57
Q

What is Nelson’s syndrome?

A

Nelson’s syndrome occurs due to rapid enlargement of a pituitary corticotroph adenoma (ACTH producing adenoma) that occurs after the removal of both adrenal glands (bilateral adrenalectomy) which is an operation used for Cushing’s syndrome.

58
Q

What are the clinical features of Nelson’s syndrome?

A

Continued growth can cause mass effects due to physical compression of brain tissue. Increased production of adrenocorticotrophic hormone (ACTH) can result in increased melanocyte stimulating hormone (MSH) which can result in hyperpigmentation.

59
Q

How does insulin regime change when a patient is unwell?

A

Diabetes sick day rules: when unwell, If a patient is on insulin, they must not stop it due to the risk of diabetic ketoacidosis. They should continue their normal insulin regime but ensure that they are checking their blood sugars frequently

60
Q

Should a patient continue taking oral hypoglycaemics while unwell?

A
  • metformin: stop treatment if there is a risk of dehydration, to reduce the risk of lactic acidosis.
  • sulfonylureas: may increase the risk of hypoglycaemia
  • SGLT-2 inhibitors: check for ketones and stop treatment if acutely unwell and/or at risk of dehydration, due to the risk of euglycaemic DKA
  • GLP-1 receptor agonists: stop treatment if there is a risk of dehydration, to reduce the risk of AKI
61
Q

What diabetic medication is contraindicated in heart failure?

A

Pioglitazone - can cause fluid retention

62
Q

What is the management of diabetic neuropathy?

A
  • first-line treatment: amitriptyline, duloxetine, gabapentin or pregabalin
  • if the first-line drug treatment does not work try one of the other 3 drugs
  • tramadol may be used as ‘rescue therapy’ for exacerbations of neuropathic pain
  • topical capsaicin may be used for localised neuropathic pain (e.g. post-herpetic neuralgia)
  • pain management clinics may be useful in patients with resistant problems
63
Q

What electrolyte abnormality is seen in Cushing’s syndrome?

A

hypokalaemic metabolic alkalosis

64
Q

What type of drug is empagliflozin

A

SGLT-2 inhibitor

65
Q

What is Primary ciliary dyskinesia

A

Reduced cilia motility throughout the body. This results in recurrent chest infections and bronchiectasis but also can result in male infertility.

When Primary ciliary dyskinesia (PCD) is associated with situs inversus (resulting in the quiet heart sounds), it is known as Kartagener’s syndrome

66
Q

What are the clinical features of Kartagener’s syndrome?

A
  • dextrocardia or complete situs inversus
  • bronchiectasis
  • recurrent sinusitis
  • subfertility (secondary to diminished sperm motility and defective ciliary action in the fallopian tubes)
67
Q

Why is a CT performed for patients with myasthenia gravis?

A

To look for a possible thymoma

68
Q

What is a common side effect of SGLT-2 inhibitors

A

increased risk of UTIs

69
Q

diagnosis?

A

Cushing’s DISEASE

Cushing’s disease is the result of the pituitary source of ACTH. There is a suppression of cortisol levels following a high dose of dexamethasone, resulting in appropriate negative feedback through the Hypothalamic-Pituitary-Adrenal (HPA) axis, suppressing both ACTH and cortisol.

70
Q

What is sick euthyroid syndrome?

A

In sick euthyroid syndrome (now referred to as non-thyroidal illness) it is often said that everything (TSH, thyroxine and T3) is low. In the majority of cases however the TSH level is within the >normal range (inappropriately normal given the low thyroxine and T3).

Changes are reversible upon recovery from the systemic illness and hence no treatment is usually needed.

71
Q

How should Iron / calcium carbonate tablets be taken with levothyroxine

A

4 hours apart
can reduce the absorption of levothyroxine

72
Q

How can Glucocorticoids affect neutrophil count?

A

Neutrophilia

73
Q

What electrolyte abnormality is seen in Conn’s syndrome?

A

Metabolic alkalosis
Hypokalaemia

74
Q

Hypercalcaemia + bilateral hilar lymphadenopathy?

A

sarcoidosis

75
Q

what type of drug is gliclazide

A

sulphonylurea

best choice for a second intensification in non-obese patients (cause weight gain)

side-effect of hypoglycaemia therefore avoided if e.g. patient a professional driver

76
Q

what type of drug is sitagliptin

A

DPP-4 inhibitor

best choice if obese

77
Q

characteristic X-ray finding of hyperparathyroidism?

A

Pepperpot skull

78
Q

What is a screening test for diabetic neuropathy affecting the feet?

A

Test sensation using a 10 g monofilament

79
Q

What Endocrine parameters are reduced in stress response e.g. major surgery ?

A

Insulin
Testosterone
Oestrogen

80
Q

What Endocrine parameters are increased in stress response e.g. major surgery ?

A

Catecholamines
Cortisol
glucagon
growth hormone.

81
Q

treatment for a phaeochromocytoma?

A

Surgery is the definitive management.

The patient must first however be stabilized with medical management:

  • alpha-blocker (e.g. phenoxybenzamine), given before a
  • beta-blocker (e.g. propranolol)
82
Q

Causes of pseudo-Cushing’s syndrome?

A

depression, HIV infection, and excess alcohol consumption

83
Q

results indicating De Quervain’s thyroiditis?

A

↑ T4
↑ ESR
↓ Uptake of iodine-131

84
Q

What conditions make up multiple endocrine neoplasia type IIa ?

A

Medullary thyroid cancer
Hypercalcaemia (Parathyroid hyperplasia)
Phaeochromocytoma

85
Q

What is gastroperesis?

A

occurs secondary to autonomic neuropathy

symptoms include erratic blood glucose control, bloating and vomiting

management options include metoclopramide, domperidone or erythromycin (prokinetic agents)

86
Q

management neuropathic pain?

A

First-line = amitriptyline, duloxetine, gabapentin or pregabalin
Second line = try one of the other 3 drugs
Third line = pain management clinics

Tramadol may be used as ‘rescue therapy’ for exacerbations of neuropathic pain

Topical capsaicin may be used for localised neuropathic pain (e.g. post-herpetic neuralgia)

87
Q

Symptoms of vitamin C deficiency ?

A
  • gingivitis, loose teeth
  • poor wound healing
  • bleeding tendency - gums, haematuria, epistaxis
  • general malaise
88
Q

Acid - base disturbance in Cushing’s syndrome ?

A

hypokalaemic metabolic alkalosis

89
Q

Optimal treatment in HNF1A-MODY ?

A

Sulfonylureas

90
Q

How is diabetic nephropathy screened for ?

A
  • All patients should be screened annually using urinary ACR
  • Should be an early morning specimen
  • May be on a spot sample if first-pass sample is not provided (but should be repeated on a first-pass specimen if abnormal)
  • ACR > 2.5 = microalbuminuria
91
Q

How is diabetic nephropathy managed ?

A
  • dietary protein restriction
  • tight glycaemic control
  • BP control: aim for < 130/80 mmHg
  • ACE inhibitor or ARB should start if urinary ACR =/>3 mg/mmol
  • control dyslipidaemia e.g. Statins
92
Q

Management of severe (<2.5) / symptomatic hypokalaemia?

A
  • Transfer to high care area with cardiac monitoring
  • IV replacement
  • If there are no contraindications to fluid therapy (e.g. volume overload, heart failure) potassium should be diluted to low concentrations as higher concentrations can be phlebitic
  • The infusion rate should not exceed 20mmol/hr
  • E.g. 3 x 1L bags of 0.9% Saline with 40mmol KCL
93
Q

ECG changes in hypokalaemia ?

A

U waves
T wave flattening
ST segment changes

94
Q

Management of mild-moderate hypokalaemia ?

A

2.5 - 3.4 mmol/l

  • Oral potassium
  • Provided patient is not symptomatic and no ECG changes
95
Q

Most common cause of peritonitis secondary to peritoneal dialysis?

A

Coagulase-negative staphylococci such as Staphylococcus epidermidis

96
Q
A